Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4163178
Max Phase: Preclinical
Molecular Formula: C88H114N16O18
Molecular Weight: 1683.97
Molecule Type: Unknown
Associated Items:
ID: ALA4163178
Max Phase: Preclinical
Molecular Formula: C88H114N16O18
Molecular Weight: 1683.97
Molecule Type: Unknown
Associated Items:
Canonical SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)NCC(=O)NCCCCCC(=O)NCCC(=O)N[C@H](CCCCNC(=O)CCNC(=O)CCCCCNC(=O)CCNC(=O)CNC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
Standard InChI: InChI=1S/C88H114N16O18/c89-67(48-58-30-34-64(105)35-31-58)86(119)103-47-17-27-72(103)85(118)102-70(50-57-18-4-1-5-19-57)83(116)101-71(51-62-24-16-23-60-20-10-11-25-66(60)62)82(115)98-54-80(113)96-45-39-77(110)91-41-13-2-6-28-74(107)94-44-38-76(109)92-43-15-12-26-69(88(121)122)100-78(111)40-46-95-75(108)29-7-3-14-42-93-79(112)53-97-81(114)55-99-84(117)73-52-61-21-8-9-22-63(61)56-104(73)87(120)68(90)49-59-32-36-65(106)37-33-59/h1,4-5,8-11,16,18-25,30-37,67-73,105-106H,2-3,6-7,12-15,17,26-29,38-56,89-90H2,(H,91,110)(H,92,109)(H,93,112)(H,94,107)(H,95,108)(H,96,113)(H,97,114)(H,98,115)(H,99,117)(H,100,111)(H,101,116)(H,102,118)(H,121,122)/t67-,68-,69+,70-,71+,72-,73+/m0/s1
Standard InChI Key: CLNBJAPGQALKME-NQWOLCANSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1683.97 | Molecular Weight (Monoisotopic): 1682.8497 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Olson KM, Keresztes A, Tashiro JK, Daconta LV, Hruby VJ, Streicher JM.. (2018) Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice., 61 (14): [PMID:29939746] [10.1021/acs.jmedchem.8b00403] |
Source(1):